Recalls of prescription drugs, over-the-counter medications, and compounded pharmaceuticals.
Showing 221–240 of 771 recalls
Xiamen Kang Zhongyuan Biotechnology Co., Ltd.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
Fagron Compounding Services
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port